Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University101 First Affiliated Hospital of Zhejiang University100 AstraZeneca74 Zhejiang Cancer Hospital65
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Hangzhou

1819 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
36
Hangzhou
2024-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
126
Hangzhou
2024-11-30
Recruiting
Lee's Pharmaceutical Limited
Phase 3
440
Hefei, Beijing, Wuhan, Changsha, Hangzhou
2024-11-28
Active, closed
Santen Pharmaceutical Co., Ltd.
Phase 3
345
Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang
2024-11-28
Recruiting
BeOne Medicines
Phase 1/2
80
Fuzhou, Guangzhou, Suzhou, Hangzhou, Wenzhou
2024-11-27
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
120
Hangzhou
2024-11-27
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
600
Hangzhou
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Recruiting
Pharmacokinetic Study of Tranexamic Acid
NCT06728670Ovarian Neoplasm Epithelial
Zhejiang Cancer Hospital
Not applicable
30
Hangzhou
2024-11-20
Recruiting
Zhejiang Provincial People's Hospital
Phase 2
57
Hangzhou
2024-11-15
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 1/2
63
Hangzhou
2024-11-15
Active, closed
BeOne Medicines
Phase 2
94
Fuzhou, Zhengzhou, Changzhou, Nanjing, Shanghai, Hangzhou
2024-11-14
Not yet open
Sir Run Run Shaw Hospital
Phase 2
76
Fuzhou, Guangzhou, Shanghai, Hangzhou
2024-11-14
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
40
Hangzhou
2024-11-13
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
100
Hangzhou
2024-11-12
Recruiting
Chongqing Precision Biotech Co., Ltd
Phase 1
18
Hangzhou
2024-11-11
Recruiting
Electroacupuncture Regulation of Immune Cells in Herpes Zoster
NCT06643247Herpes Zoster, Electroacupuncture, Immune
First People's Hospital of Hangzhou
Not applicable
8
Hangzhou
2024-11-11
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
158
Hangzhou
2024-11-10
Recruiting
Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
NCT06658080Breast Cancer Metastatic, Hydrothorax, Ascites, Organoids
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
90
Hangzhou
2024-11-09
Recruiting
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
152
Nanning, Zhengzhou, Wuhan, Hangzhou, Shanghai
2024-11-08
Active, closed
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
Zhejiang Cancer Hospital
Phase 2
44
Hangzhou
2024-11-06
Recruiting
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
NCT06641609Non-Small Cell Lung Cancer With EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
Phase 1
166
Hangzhou
2024-11-04
Recruiting
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
NCT07014449AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
Hangzhou Weben Pharma Co., Ltd
Phase 1
36
Hangzhou
2024-11-03
By invitation
Evaluation of Endoscopic Treatment Effect Based on HVPG
NCT06863519Esophageal and Gastric Varices
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
50
Hangzhou
2024-11-01
Not yet open
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
NCT06704542ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
Ruijin Hospital
Observational
1,000
Zhengzhou, Wuhan, Shanghai, Hangzhou, Tianjin
2024-11
Not yet open
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
120
Beijing, Nanning, Zhengzhou, Shanghai, Hangzhou
2024-11
Not yet open
Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging
NCT06681155Coronary Arterial Disease (CAD), Acute Coronary Syndromes
Chinese PLA General Hospital
Observational
500
Shenzhen, Wuhan, Changchun, Xi'an, Ürümqi, Hangzhou, Beijing
2024-11
Not yet open
Qilu Pharmaceutical Co., Ltd.
Phase 3
786
Hangzhou
2024-10-31
Recruiting
Brii Biosciences Limited
Phase 2
250
Beijing, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-10-31
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2024-10-30
Recruiting
Multicenter iTBS Neuromodulation for PTSD Treatment
NCT06434766Posttraumatic Stress Disorder
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Shanghai, Hangzhou, Ningbo
2024-10-30
Active, closed
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
178
Hangzhou
2024-10-30
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
2024-10-29
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
184
Hangzhou
2024-10-25
Recruiting
Shanghai Zhongshan Hospital
Phase 2
100
Shantou, Shenyang, Shanghai, Tianjin, Hangzhou
2024-10-24
Recruiting
Zheng Yabing
Observational
200
Hangzhou
2024-10-24
Recruiting
Zhejiang University
Phase 1
58
Beijing, Xi’an, Hangzhou
2024-10-23
Recruiting
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
NCT06633354T-Acute Lymphoblastic Leukemia
Zhejiang University
Early Phase 1
30
Hangzhou
2024-10-20
Recruiting
Zhejiang University
Early Phase 1
30
Hangzhou
2024-10-20
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
30
Hangzhou
2024-10-18
Recruiting
Fudan University
Phase 4
756
Harbin, Changzhou, Nanjing, Yangzhou, Shanghai, Hangzhou, Ningbo
2024-10-18
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Recruiting
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
NCT06742515Precursor B-Cell Acute Lymphoblastic Leukemia
DrugBlinatumomab
First Affiliated Hospital of Zhejiang University
Phase 2
20
Hangzhou
2024-10-17
Active, closed
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
12
Shanghai, Hangzhou
2024-10-16
Not yet open
Peking University Third Hospital
Early Phase 1
7
Beijing, Fujian, Nanjing, Chengdu, Hangzhou
2024-10-16
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
24
Hangzhou
2024-10-15
Recruiting
Xiangdong Cheng
Phase 1
40
Hangzhou
2024-10-15
Recruiting
Boehringer Ingelheim
Phase 2
588
Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan
2024-10-11
Active, closed
Immune Cell Subsets in SLE Patients Treated with Telitacicept
NCT06677801Systemic Lupus Erythematosus (SLE)
DrugTelitacicept
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
50
Hangzhou
2024-10-11
Recruiting
Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy
NCT05824520Coronary Artery Disease, Myocardial Ischaemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,066
Hangzhou
2024-10-10
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
29
Hangzhou
2024-10-10
Recruiting
Sir Run Run Shaw Hospital
Not applicable
2,000
Hangzhou
2024-10-09
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
35
Nanchang, Hangzhou, Harbin, Hefei, Jinhua, Nantong, Shanghai, Shanxi
2024-10-09
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
52
Hangzhou
2024-10-08
Recruiting
Hansoh BioMedical R&D Company
Phase 1
560
Hangzhou
2024-10-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
78
Hangzhou
2024-10-01
Not yet open
Sir Run Run Shaw Hospital
Phase 2
80
Hangzhou
2024-10
Active, closed
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Exploration of Gender Differences in Liver Aging
NCT06591897Healthy Population
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
18
Hangzhou
2024-09-27
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-09-26
Recruiting
Chaohui Yu
Early Phase 1
18
Hangzhou
2024-09-24
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,000
Hangzhou
2024-09-23
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-09-20
Recruiting
Blinatumomab for CNI-Resistant/Intolerant SRNS in Children
NCT06607991CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent, Steriod Resistant Nephrotic Syndrome, Multidrug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
6
Hangzhou
2024-09-19
Recruiting
Zhejiang Cancer Hospital
Not applicable
214
Hangzhou
2024-09-18
Recruiting
AstraZeneca
Phase 1/2
174
Hangzhou, Shanghai
2024-09-18
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
99
Hefei, Fuzhou, Quanzhou, Xiamen, Zhangzhou, Shanghai, Hangzhou
2024-09-11
Recruiting
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Active, closed
Jichao Qin
Observational
1,200
Hangzhou
2024-09-11
Active, closed
Women's Hospital School Of Medicine Zhejiang University
Observational
200
Hangzhou
2024-09-10
Recruiting
Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China
NCT07113808Abdominal Neoplasm, Abdominal Injury, Ascites
DrugSonoVue
The Children's Hospital of Zhejiang University School of Medicine
Observational
108
Hangzhou
2024-09-10
Recruiting
Hangzhou Valgen Medtech Co., Ltd
Not applicable
236
Chengdu, Hangzhou
2024-09-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2024-09-01
Recruiting
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
NCT06572319HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
DrugDisitamab Vedotin
Zhejiang Cancer Hospital
Phase 1/2
35
Hangzhou
2024-09-01
Active, closed
Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study
NCT06330233Diabetic Peripheral Neuropathy, Pain, Moxibustion, Randomized Controlled Trial
Zhejiang Chinese Medical University
Not applicable
90
Hangzhou
2024-09-01
Recruiting
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
152
Hangzhou
2024-09-01
Not yet open
The First Affiliated Hospital of Zhejiang Chinese Medical University
Not applicable
2,000
Hangzhou
2024-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2024-09-01
Recruiting
Prospective Observational Cohort Study of Moderate Aortic Valve Disease
NCT06595992Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation, Aortic Valve Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2024-09-01
Recruiting
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
NCT06523673Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
104
Hangzhou
2024-09
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Active, closed
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Active, closed
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
Active, closed
Chinese PLA General Hospital
Observational
3,000
Beijing, Hangzhou
2024-08-27
Active, closed
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
116
Hangzhou
2024-08-26
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
108
Hangzhou
2024-08-23
Active, closed
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
70
Hangzhou
2024-08-21
Recruiting
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou
2024-08-20
Active, closed
Oneness Biotech Co., Ltd.
Phase 2/3
120
Jiangmen, Luoyang, Suzhou, Zhenjiang, Shenyang, Xi'an, Hangzhou, Guangzhou
2024-08-16
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
20
Hangzhou
2024-08-15
Not yet open
Zhejiang University
Not applicable
200,000
Hangzhou
2024-08-15
Active, closed
Bolt CSP-M Holter Study
NCT06540521Heart Failure, Bradycardia
Medtronic Cardiac Rhythm and Heart Failure
Observational
95
Shanghai, Hangzhou
2024-08-13
Recruiting
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
NCT06553898Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2024-08-13
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
Zhejiang University
Not applicable
5
Hangzhou
2024-08-10
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Phase 1/2
10
Hangzhou
2024-08-09
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
35
Hangzhou
2024-08-08
Active, closed
AbbVie
Phase 3
111
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-08-07
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
Akeso
Phase 3
469
Zhengzhou, Changsha, Nanjing, Hangzhou
2024-08-02
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
68
Hangzhou
2024-08-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031Crohn Disease, Stricture; Bowel, Intestinal Stricture
DrugUstekinumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
239
Beijing, Chongqing, Guangzhou, Huai'an, Suzhou, Yangzhou, Hangzhou
2024-08-01
Recruiting
Zhejiang Cancer Hospital
Phase 2
92
Hangzhou
2024-08-01
By invitation
Zhejiang Provincial People's Hospital
Observational
200
Hangzhou
2024-08-01
Recruiting
The Affiliated Hospital of Hangzhou Normal University
Not applicable
2,000
Hangzhou
2024-08-01
Not yet open
Zhejiang University
Observational
3,000
Hangzhou
2024-08-01
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08-01
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Active, closed
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
216
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanning, Nantong, Qingdao
2024-07-30
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
70
Hangzhou
2024-07-30
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2024-07-29
Recruiting
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
NCT06821048Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
Weijia Fang, MD
Phase 1
18
Hangzhou
2024-07-24
Recruiting
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
NCT06562920Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou
2024-07-24
Recruiting
Prediction of Significant Liver Fibrosis
NCT06509230Liver Fibrosis
Huang Haijun
Observational
700
Hangzhou
2024-07-20
Recruiting
Shanghai Mabgeek Biotech.Co.Ltd
Phase 1/2
24
Hangzhou
2024-07-19
Recruiting
Zhejiang Provincial People's Hospital
Phase 3
848
Hangzhou
2024-07-18
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
60
Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-07-17
Recruiting
He Huang
Phase 4
118
Hangzhou
2024-07-17
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
NCT06534762NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
DrugMirabegron
Zhejiang Provincial People's Hospital
Phase 2
260
Hangzhou
2024-07-15
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang
2024-07-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
400
Hangzhou
2024-07-10
Recruiting
Zhejiang Cancer Hospital
Phase 1/2
90
Hangzhou
2024-07-10
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Guangzhou, Zhengzhou, Wuhan, Changsha, Shang'ai, Shanghai, Chengdu, Hangzhou
2024-07-09
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
42
Hangzhou
2024-07-08
Recruiting
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
NCT06484816Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
Shenzhen TargetRx Co., Ltd.
Phase 1
90
Hangzhou
2024-07-08
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
72
Hangzhou
2024-07-05
Active, closed
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Recruiting
Zhejiang Cancer Hospital
Phase 3
312
Hangzhou
2024-07-03
Recruiting
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
NCT06424665Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
DrugFZ-AD005
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
162
Changsha, Shanghai, Hangzhou
2024-07-03
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
156
Zhengzhou, Hangzhou
2024-07-02
Recruiting
Chongqing Precision Biotech Co., Ltd
Phase 1
10
Hangzhou
2024-07-02
Recruiting
Xiangdong Cheng
Observational
100,000
Hangzhou
2024-07-01
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Recruiting
Zhejiang University
Phase 1
15
Hangzhou
2024-07-01
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou
2024-07-01
Recruiting
Study of Clostridioides Difficile in Infants
NCT06788769Clostridioides Difficile Infection
Westlake University
Observational
300
Hangzhou
2024-07-01
Active, closed
Ruijin Hospital
Phase 3
250
Wuhan, Shanghai, Hangzhou
2024-07-01
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
400
Hangzhou
2024-07-01
Recruiting
Zhejiang Provincial People's Hospital
Phase 3
60
Hangzhou
2024-07-01
Recruiting
The First Affiliated Hospital of Zhejiang Chinese Medical University
Early Phase 1
410
Hangzhou
2024-07-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
420
Hangzhou
2024-07-01
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
93
Nanjing, Hangzhou
2024-07-01
Recruiting
Study on Clostridium Difficile Infection in Infants
NCT06703918Clostridium Difficile Infection
First People's Hospital of Hangzhou
Observational
150
Hangzhou
2024-07-01
Active, closed
Haixing Ju, MD
Phase 3
896
Hangzhou
2024-07-01
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
69
Hangzhou
2024-06-28
Recruiting
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
NCT06741553Alzheimer Disease, Mild Cognitive Impairment (MCI)
DrugLecanemab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
120
Hangzhou
2024-06-28
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
222
Hangzhou, Ningbo, Wenzhou
2024-06-25
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
488
Hangzhou
2024-06-22
Recruiting
Jin Ying
Phase 2
38
Hangzhou
2024-06-21
Recruiting
AstraZeneca
Phase 3
240
Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing
2024-06-20
Not yet open
First People's Hospital of Hangzhou
Not applicable
22
Hangzhou
2024-06-20
Recruiting
The Peripheral Blood Multi-Omics Study on Sleep Loss
NCT06492109Sleep Deprivation, Aging, Alzheimer Disease, Healthy Lifestyle
First Affiliated Hospital of Zhejiang University
Not applicable
60
Hangzhou
2024-06-20
Recruiting
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
NCT06464861Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
52
Hangzhou
2024-06-20
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Recruiting
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
1,860
Dongyang, Hangzhou, Jinhua, Lishui, Ningbo, Quzhou, Taizhou, Wenling
2024-06-19
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Early Phase 1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
Zhejiang Provincial People's Hospital
Phase 4
450
Hangzhou, Huzhou, Taizhou, Zhoushan
2024-06-16
Recruiting
Ascentage Pharma Group Inc.
Phase 3
486
Tianjin, Hangzhou
2024-06-11
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, Ürümqi, Xi'an
2024-06-11
Active, closed
GlaxoSmithKline
Phase 3
88
Chengdu, Hangzhou, Hefei, Nanjing, Shanghai
2024-06-10
Recruiting
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
NCT06976177Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
DrugMT1013
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase 2
310
Hangzhou
2024-06-07
Recruiting
A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
NCT06881498Bone Tumor, Acute Normovolemic Hemodilution, Goal-Directed Fluid Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
32
Hangzhou
2024-06-07
Recruiting
The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
NCT06459141Acute Normovolemic Hemodilution, Bone Tumor, Goal-Directed Fluid Therapy, Transfusion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
150
Hangzhou
2024-06-07
Recruiting
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Jinan, Hangzhou
2024-06-05
Recruiting
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT06413342Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
DrugSintilimab
Zhejiang Cancer Hospital
Phase 2
191
Hangzhou
2024-06-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2024-06-01
Recruiting
Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
NCT06445881Non Small Cell Lung Cancer, Perioperative Complication
First Affiliated Hospital of Zhejiang University
Phase 2
60
Hangzhou
2024-06-01
Recruiting
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
NCT06346912Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell
Zhejiang University
Early Phase 1
20
Hangzhou
2024-05-30
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin
2024-05-28
Recruiting
Hansoh BioMedical R&D Company
Phase 2/3
1,080
Tianjin, Hangzhou
2024-05-28
Recruiting
Hutchmed
Phase 1
132
Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan
2024-05-27
Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
NCT06421948Peripheral T-cell Lymphoma
Yanyan Liu
Phase 1/2
134
Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou
2024-05-25
Recruiting
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
24
Hangzhou
2024-05-23
Recruiting
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
Recruiting
Xie Kangjie
Observational
180
Duyun, Hangzhou
2024-05-20
Recruiting
Zeng Jian
Phase 2
92
Hangzhou
2024-05-19
Recruiting
Screening of Biomarkers and Related Mechanisms for RIX
NCT07170358Xerostomia Due to Radiotherapy (Disorder)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
50
Nanjing, Hangzhou
2024-05-17
By invitation
First Affiliated Hospital of Zhejiang University
Observational
375
Hangzhou
2024-05-13
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
440
Beijing, Hangzhou
2024-05-10
Active, closed
Sanofi
Phase 3
1,541
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan
2024-05-08
Recruiting
AMT-116 in Patients with Solid Tumors
NCT06782334Advanced Solid Tumors
DrugAMT-116
Multitude Therapeutics Inc.
Phase 1/2
144
Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou
2024-05-07
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
244
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-05-07
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
87
Hangzhou
2024-05-04
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
580
Hangzhou, Hanzhou
2024-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
25
Hangzhou
2024-05-01
Recruiting
Jichao Qin
Observational
150
Hangzhou
2024-05-01
Recruiting
Ji Yongling
Phase 2
20
Hangzhou
2024-05-01
Recruiting
Jichao Qin
Observational
100
Hangzhou
2024-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
120
Hangzhou
2024-05-01
Recruiting
Jichao Qin
Observational
200
Hangzhou
2024-05-01
By invitation
Li hengjie
Observational
1,500,000
Hangzhou
2024-05-01
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
500
Hangzhou
2024-05
Recruiting
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b
NCT06217861Glutaric Acidemia Type I, Glutaric Aciduria Type I
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1
12
Hangzhou
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai
2024-04-26
Not yet open
Xiangdong Cheng
Phase 2
134
Hangzhou
2024-04-25
Recruiting
First People's Hospital of Hangzhou
Phase 2
40
Hangzhou
2024-04-24
Active, closed
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
Shandong University
Phase 2
83
Changsha, Nanjing, Jinan, Qingdao, Taiyuan, Hangzhou
2024-04-15
Recruiting
Zhejiang University
Early Phase 1
45
Hangzhou
2024-04-15
Active, closed
Bio-Thera Solutions
Phase 1/2
112
Hangzhou
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 3
81
Hangzhou
2024-04-03
Recruiting
Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease
NCT06431711Cerebral Small Vessel Diseases, Retinal Ischemia, Choroid; Injury
Zhejiang Provincial People's Hospital
Observational
2,400
Hangzhou
2024-04-01
Recruiting
Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy (EMBRACE Study)
NCT06451887Endovascular Therapy, Brain Edema, Prediction Model, Ischemic Stroke
Zhejiang Provincial People's Hospital
Observational
1,950
Hangzhou
2024-04-01
Recruiting
Hangzhou Medical College
Not applicable
220
Hangzhou
2024-04-01
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Active, closed
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Active, closed
Septal Ablation for Obstructive HCM
NCT06277960Hypertrophic Obstructive Cardiomyopathy (HOCM)
SuZhou Sinus Medical Technologies Co.,Ltd
Not applicable
20
Hangzhou
2024-03-28
Active, closed
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
260
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Recruiting
Zhejiang Cancer Hospital
Phase 2
40
Hangzhou
2024-03-22
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
By invitation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
133
Hangzhou
2024-03-19
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2024-03-16
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
30
Hangzhou
2024-03-16
Recruiting
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
By invitation
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
200
Hangzhou
2024-03-09
Recruiting
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2
24
Guangzhou, Hangzhou
2024-03-07
Recruiting
Fudan University
Phase 2
210
Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo
2024-03-04
Active, closed
AstraZeneca
Phase 3
594
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-03-04
Active, closed
Multicenter Study on the Use of Intraoperative OCT in the Diagnosis and Management of Lens Diseases
NCT07741370Lens Diseases, Cataract, Age-related Cataract, Complicated Cataract
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,200
Hangzhou
2024-03-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
20
Hangzhou
2024-03-01
Active, closed
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-01
Recruiting
Zhejiang Cancer Hospital
Phase 2
146
Hangzhou
2024-03-01
Active, closed
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
27
Hangzhou
2024-02-28
Recruiting
Daiichi Sankyo
Phase 2/3
860
Xi’an, Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning
2024-02-27
Recruiting
Skyline Therapeutics (US) Inc.
Phase 1/2
68
Hefei, Hangzhou, Wenzhou, Beijing
2024-02-23
Active, closed
AstraZeneca
Phase 2
127
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongyang, Guangzhou, Hangzhou
2024-02-22
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
50,000
Hangzhou
2024-02-21
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
414
Hangzhou
2024-02-19
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Active, closed
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
22
Hangzhou
2024-02-10
Active, closed
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Recruiting
The Third People's Hospital of Hangzhou
Not applicable
102
Hangzhou
2024-02-07
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Hangzhou
2024-02-05
Active, closed
TingBo Liang
Phase 1
18
Hangzhou
2024-02-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
104
Hangzhou
2024-01-25
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
Hangzhou, Beijing, Guangzhou
2024-01-25
Active, closed
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Advanced Solid Tumors, Hematological Malignancies
DrugDXC006
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
280
Hefei, Guangzhou, Changsha, Nanchang, Hangzhou
2024-01-24
Recruiting
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1
60
Hangzhou
2024-01-23
Active, closed
Sanofi
Phase 3
260
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2024-01-23
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Recruiting
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
NCT06214195Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Zhejiang Cancer Hospital
Phase 3
276
Hangzhou
2024-01-20
Active, closed
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
50
Changsha, Dongguan, Guangzhou, Hangzhou, Hefei, Shenzhen
2024-01-13
Recruiting
The Dental Hospital of Zhejiang University School of Medicine
Observational
83
Hangzhou
2024-01-11
Recruiting
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
NCT06220617Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma
Zhejiang University
Observational
3,600
Hangzhou, Guangzhou, Kunming, Nanjing, Xi'an, Zhengzhou
2024-01-11
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,182
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-01-11
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
68
Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou
2024-01-11
Recruiting
Steroid Diabetes in Patients With Kidney Disease
NCT06161701Nephrotic Syndrome
Zhejiang Provincial People's Hospital
Observational
300
Hangzhou
2024-01-10
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
300
Hangzhou
2024-01-10
Recruiting
Shanghai Lanyi Therapeutics Co., Ltd.
Phase 1
24
Tianjin, Hangzhou
2024-01-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Hangzhou
2024-01-03
Recruiting
Chuanlong Zhou
Not applicable
96
Hangzhou
2024-01-01
Active, closed
Ling Zhiqiang
Observational
300
Hangzhou
2024-01-01
Recruiting
Sir Run Run Shaw Hospital
Phase 2
30
Hangzhou
2024-01-01
Recruiting
Pengyuan Liu
Phase 2
60
Hangzhou
2024-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
286
Hangzhou
2024-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
24
Xi'an, Hangzhou
2024-01-01
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
128
Hangzhou
2024-01-01
Active, closed
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
NCT07437170Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid Leukemia
DrugSelinexor
The Children's Hospital of Zhejiang University School of Medicine
Phase 2
10
Hangzhou
2024-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,000
Hangzhou
2024-01-01
Recruiting
Dementia Risk Registry Across the Multidimensional Lifespan: A 10-Year Study
NCT06164262Cerebral Small Vessel Diseases, Dementia, Mixed, Health Behavior, Health Behavior, Risky
Zhejiang Provincial People's Hospital
Observational
1,000
Hangzhou
2024-01-01
Recruiting
The First Affiliated Hospital of Zhejiang Chinese Medical University
Observational
40
Hangzhou
2024-01-01
Not yet open
Zhejiang Cancer Hospital
Phase 1/2
220
Hangzhou
2024-01
Recruiting
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Active, closed
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Recruiting
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xi’an, Tianjin, Hangzhou
2023-12-27
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
NCT05872685Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
DrugsSerplulimab·Oxaliplatin
Yu jiren
Phase 2
314
Hangzhou, Lishui, Ningbo, Taizhou
2023-12-24
Recruiting
Janssen Research & Development, LLC
Phase 1
300
Beijing, Hangzhou, Tianjin
2023-12-20
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Recruiting
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase 1
84
Hangzhou
2023-12-08
Recruiting
Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
NCT06155305Organoids, Breast Cancer, Neoadjuvant Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
58
Hangzhou
2023-12-06
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
100
Hangzhou
2023-12-04
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
210
Hangzhou
2023-12-01
Active, closed
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Ha’erbin, Jinan
2023-12-01
Recruiting
Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
NCT06417736Endometrial Cancer Stage I, Endometrial Hyperplasia
DrugMegestrol Acetate
Women's Hospital School Of Medicine Zhejiang University
Not applicable
75
Hangzhou
2023-12-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
150
Hangzhou
2023-12-01
Active, closed
Rapid Abdominal Diagnosis With AI & Radiology
NCT07040358Abdominal Diseases
First Affiliated Hospital of Zhejiang University
Observational
2,000,000
Hangzhou
2023-12-01
Not yet open
Zhejiang Cancer Hospital
Phase 1/2
58
Hangzhou
2023-11-30
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
20
Hangzhou
2023-11-28
Recruiting
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
DrugsNab-paclitaxel·Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3
538
Guangzhou, Ji'nan, Hangzhou, Ningbo, Wenzhou
2023-11-27
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
84
Hangzhou
2023-11-23
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
57
Hangzhou
2023-11-21
Recruiting
He Huang
Early Phase 1
18
Hangzhou
2023-11-16
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2/3
166
Beijing, Hangzhou
2023-11-16
Active, closed
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Recruiting
LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
NCT07252362The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals
Zhejiang Cancer Hospital
Not applicable
20
Hangzhou
2023-11-11
Active, closed
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Active, closed
Bristol-Myers Squibb
Phase 2
227
Beijing, Guangzhou, Luoyang, Changsha, Hangzhou
2023-11-07
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Relma-cel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
Zhejiang University
Early Phase 1
7
Hangzhou
2023-11-02
Recruiting
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
NCT06139042Liver Cancer, Biliary Tract Cancer, Pancreatic Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,608
Hangzhou
2023-11-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
160
Hangzhou
2023-11-01
Recruiting
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer
NCT07504523Metastatic Colorectal Cancer (CRC)
Ying Yuan, MD
Phase 1
20
Hangzhou
2023-11-01
Recruiting
Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN
NCT05842109ABO Hemolytic Disease of Newborn
Women's Hospital School Of Medicine Zhejiang University
Observational
112
Hangzhou
2023-10-31
Recruiting
Preventive Effect of Probiotics in GDM
NCT06938464Gestational Diabetes Mellitus (GDM)
Women's Hospital School Of Medicine Zhejiang University
Not applicable
334
Hangzhou
2023-10-27
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
2,618
Hangzhou
2023-10-26
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
100
Hangzhou
2023-10-26
By invitation
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
NCT06481956HER2-positive Advanced Breast Cancer
DrugRibociclib
Zheng Yabing
Phase 2
40
Hangzhou
2023-10-25
Recruiting
Zhejiang Cancer Hospital
Phase 2
31
Hangzhou
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-10-24
Active, closed
Zhejiang Cancer Hospital
Phase 2
40
Hangzhou
2023-10-24
Active, closed
Otsuka Beijing Research Institute
Phase 1/2
72
Hangzhou
2023-10-16
Not yet open
GrandPharma (China) Co., Ltd.
Observational
200
Hangzhou
2023-10-15
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Chengdu, Hangzhou, Jinan, Nanchang, Shanghai
2023-10-13
Recruiting
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
1,080
Hangzhou
2023-10-10
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
Recruiting
Pfizer
Phase 4
80
Beijing, Guangzhou, Jinan, Hangzhou
2023-10-03
Recruiting
FBD Biologics Limited
Phase 1
80
Hangzhou
2023-10-02
Recruiting
AbbVie
Phase 3
90
Chongqing, Suzhou, Xi'an, Shanghai, Hangzhou
2023-10-02
Not yet open
Zhang Xiaofeng,MD
Not applicable
20
Hangzhou
2023-10-01
Recruiting
Neoadjuvant SBRT in Localized Advanced HNSCC
NCT06306846Head and Neck Squamous Carcinoma
DrugCetuximab
Jiang Feng
Phase 2
81
Hangzhou
2023-10-01
Not yet open
Fudan University
Phase 4
384
Shijiazhuang, Zhengzhou, Changsha, Nantong, Yangzhou, Shanghai, Hangzhou, Jiaxin
2023-10
Recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
56
Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou
2023-09-28
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
2,000
Hangzhou, Huzhou, Jiaxing, Lanxi, Lishui, Pinghu, Taizhou, Wenzhou
2023-09-25
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1
128
Harbin, Shanghai, Hangzhou
2023-09-19
Recruiting
A Cohort Study of Uterine Malignancies
NCT05635123Cervical Cancer, Endometrial Cancer
Women's Hospital School Of Medicine Zhejiang University
Observational
6,200
Hangzhou
2023-09-15
Active, closed
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Active, closed
Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth
NCT05698394Prenatal Depression, Ketamine, Postpartum Depression
DrugEsketamine
Peking University First Hospital
Phase 4
364
Changsha, Nanjing, Hangzhou, Beijing
2023-09-09
Recruiting
Sir Run Run Shaw Hospital
Phase 1
20
Hangzhou
2023-09-08
Recruiting
Sir Run Run Shaw Hospital
Phase 1
20
Hangzhou
2023-09-08
Recruiting
Sir Run Run Shaw Hospital
Phase 1
20
Hangzhou
2023-09-08
Recruiting
Hoffmann-La Roche
Phase 3
230
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan
2023-09-08
Active, closed
Shanghai BDgene Co., Ltd.
Phase 1
16
Shanghai, Hangzhou, Wenzhou
2023-09-04
Active, closed
Yi Zhou
Not applicable
180
Hangzhou
2023-09-01
Not yet open
Effectiveness of Ketogenic Diet in MELAS Syndrome
NCT06013397MELAS Syndrome, Ketogenic Dieting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2023-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
80
Hangzhou
2023-09-01
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Nanchang, Neijiang
2023-08-18
Active, closed
Amgen
Phase 4
36
Beijing, Fuzhou, Guangzhou, Harbin, Xi'an, Hangzhou
2023-08-17
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
248
Beijing, Shanghai, Bengbu, Changsha, Chongqing, Guizhou, Hangzhou, Henan
2023-08-12
Recruiting
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
NCT06043466Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
30
Hangzhou
2023-08-11
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Active, closed
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Active, closed
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Recruiting
Shen Chun-Hong
Observational
300
Hangzhou
2023-08-01
Active, closed
Bio-Thera Solutions
Phase 2
162
Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou
2023-08-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2023-08-01
Recruiting
GlaxoSmithKline
Phase 3
892
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2023-08-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
100
Hangzhou
2023-08
Not yet open
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Observational
89
Beijing, Chengdu, Hangzhou, Shanghai
2023-07-30
Not yet open
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
DrugsToripalimab·Oxaliplatin
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-07-28
Recruiting
RemeGen Co., Ltd.
Phase 2
120
Changsha, Shanghai, Tianjin, Hangzhou
2023-07-27
Recruiting
Incyte Corporation
Phase 1
570
Beijing, Hangzhou
2023-07-24
Recruiting
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
27
Hangzhou, Shanghai
2023-07-24
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
589
Guangzhou, Hangzhou
2023-07-14
Active, closed
Akeso
Phase 1/2
233
Hangzhou, Shanghai
2023-07-13
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou
2023-07-10
Recruiting
Metastatic Nasopharyngeal Carcinoma
NCT06886347Metastatic Nasopharyngeal Carcinoma
DrugGemcitabine
Chen Xiaozhong
Phase 1
47
Hangzhou
2023-07-07
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Active, closed
Hangzhou Converd Co., Ltd.
Phase 1
24
Hangzhou, Shanghai
2023-07-05
Recruiting
Sir Run Run Shaw Hospital
Not applicable
422
Hangzhou, Huzhou, Jinhua, Lishui, Ningbo, Quzhou, Shaoxing, Taizhou
2023-07-01
Recruiting
Zhejiang Cancer Hospital
Phase 2
35
Hangzhou
2023-07-01
Recruiting
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
NCT05914545Advanced and Metastatic Solid Tumor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
121
Hangzhou, Shanghai, Xuzhou
2023-06-21
Recruiting
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
NCT07394374Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
Cullgen (Shanghai),Inc
Phase 1/2
42
Beijing, Chengdu, Guangzhou, Hangzhou, Taiyuan
2023-06-20
Recruiting
Revascularization Effect on CSVD Burden in Carotid Artery Stenosis
NCT06031610Carotid Artery Stenosis, Cerebral Small Vessel Diseases
Zhejiang Provincial People's Hospital
Observational
1,000
Hangzhou
2023-06-10
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Active, closed
GeneCradle Inc
Phase 1/2
16
Beijing, Changsha, Hangzhou, Zhengzhou
2023-06-02
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Recruiting
Hoffmann-La Roche
Phase 3
200
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Active, closed
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
DrugsToripalimab·Oxaliplatin
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
DrugsFLOT·Trastuzumab·Toripalimab
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
By invitation
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Recruiting
A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China
NCT05886114Cognitive Impairment, Alzheimer Disease, Vascular Cognitive Impairment, Dement
Zhejiang University
Not applicable
1,200
Hangzhou
2023-05-28
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
126
Guli, Yiwu, Dongyang, Hangzhou, Jinhua, Lanxi
2023-05-28
Recruiting
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
174
Hangzhou
2023-05-18
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2023-05-16
Recruiting
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
Zhejiang University
Phase 2
49
Hangzhou
2023-05-15
Recruiting
Weijia Fang, MD
Phase 2
30
Hangzhou
2023-05-08
Active, closed
Westlake University
Observational
237
Hangzhou
2023-05-08
Recruiting
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou, Hanzhou
2023-05-05
Active, closed
Novartis Pharmaceuticals
Phase 2
63
Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou
2023-05-05
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
260
Hangzhou
2023-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
120
Hangzhou
2023-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
40
Hangzhou
2023-05-01
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
80
Hangzhou
2023-05-01
Recruiting
Zhejiang University
Phase 1/2
30
Hangzhou
2023-04-30
Recruiting
Bioray Laboratories
Phase 1
18
Wuhan, Tianjin, Hangzhou
2023-04-25
Recruiting
Chinese Academy of Medical Sciences, Fuwai Hospital
Early Phase 1
210
Beijing, Shanghai, Hangzhou
2023-04-24
Active, closed
Zhejiang Cancer Hospital
Phase 2
89
Hangzhou
2023-04-21
Recruiting
Cell Origin Biotech (Hangzhou) Co., Ltd.
Not applicable
2
Hangzhou, Linyi
2023-04-12
Active, closed
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Active, closed
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
158
Hangzhou, Jiaxing, Jinhua, Ningbo, Yiwu
2023-04-01
Recruiting
Sir Run Run Shaw Hospital
Phase 3
108
Hangzhou
2023-04-01
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Recruiting
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
NCT04937699Acute Coronary Syndrome, Percutaneous Coronary Intervention
DrugAspirin
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,690
Hangzhou
2023-03-28
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Recruiting
Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities
NCT06760221Soft Tissue Sarcoma, Stereotactic Body Radiotherapy, Surgery
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
20
Hangzhou
2023-03-23
Active, closed
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Recruiting
Effect of the Combined Programme on Perioperative Anaemia（CPPA）
NCT05353348Patient Blood Management, Cardiac Surgery, Iron Deficiency Anemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
110
Hangzhou
2023-03-15
Recruiting
BPH Global Registry
NCT05543200Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Société Internationale d'Urologie
Observational
7,500
Hangzhou
2023-03-13
Active, closed
Energy Metabolism Profiles Over Weight-loss and Eating Responses
NCT05785221Homeostasis, Metabolism and Nutrition Disorder, Healthy, Obesity
Chinese Academy of Sciences
Not applicable
117
Hangzhou
2023-03-02
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Hangzhou
2023-03-01
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
5,000
Hangzhou, Taizhou
2023-03-01
Recruiting
Zhejiang University
Phase 3
190
Hangzhou
2023-03-01
Recruiting
Zhejiang University
Not applicable
30
Hangzhou
2023-03-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
153
Hangzhou
2023-03
Not yet open
Zhejiang University
Phase 3
38
Shanghai, Hangzhou, Ningbo
2023-03
Active, closed
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
NCT06198413Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd
Phase 1
12
Hefei, Hangzhou, Shanghai
2023-02-27
Recruiting
Zhejiang University
Phase 2
50
Hangzhou
2023-02-22
Recruiting
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Active, closed
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Active, closed
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Recruiting
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase 1/2
84
Beijing, Guangzhou, Hangzhou
2023-02-09
Recruiting
Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway
NCT05913960Major Depressive Disorder, Major Depressive Disorder, Recurrent
First Affiliated Hospital of Zhejiang University
Not applicable
90
Hangzhou
2023-02-09
Recruiting
Zhejiang University
Observational
108
Hangzhou
2023-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,700
Hangzhou
2023-02-01
Recruiting
Zhejiang Cancer Hospital
Phase 2
63
Hangzhou
2023-02-01
Recruiting
Radiomics-based Malnutrition for Cervical Cancer.
NCT05709769Cervical Cancer, Malnutrition
Zhejiang Provincial People's Hospital
Observational
150
Hangzhou
2023-01-31
Recruiting
AstraZeneca
Phase 2
163
Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou
2023-01-16
Recruiting
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an
2023-01-12
Recruiting
Clinical Study of OR for Second-line Treatment of Refractory MZL
NCT06134284OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
DrugsOrelabrutinib·Rituximab
Lixia Sheng
Phase 4
39
Hangzhou, Ningbo
2023-01-02
Recruiting
Ultrasound-assisted Nasal Bone Fracture Reduction
NCT07869563Nasal Bone Fracture, Ultrasound
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou
2023-01-01
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
60
Hangzhou
2023-01-01
Recruiting
Idiopathic Generalized Epilepsy Syndromes
NCT06388174Epilepsy, Epilepsy, Idiopathic Generalized
Shen Chun-Hong
Observational
200
Hangzhou
2023-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
323
Jiangxi, Shanghai, Hangzhou
2023-01-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2023-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2023-01-01
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Guangzhou, Hangzhou, Dalian, Tianjin
2022-12-30
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Fuzhou, Changsha, Changchun, Hangzhou, Taizhou
2022-12-20
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
387
Hangzhou
2022-12-15
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Active, closed
Janssen Research & Development, LLC
Phase 3
214
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
250
Hangzhou
2022-12-08
Not yet open
Women's Hospital School Of Medicine Zhejiang University
Not applicable
140
Hangzhou
2022-12-01
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT05659251Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
48
Hangzhou
2022-12-01
Recruiting
Ningbo No. 1 Hospital
Phase 1
24
Hangzhou, Ningbo
2022-12
Active, closed
Pfizer
Phase 1
148
Hangzhou, Wenzhou
2022-11-30
Recruiting
Bio-Thera Solutions
Phase 1
182
Chongqing, Hangzhou
2022-11-30
Active, closed
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Jinan, Qingdao
2022-11-21
Active, closed
Primary Cervical Cancer Screening by Self-sampling HPV Test
NCT05613283Human Papillomavirus Infection, Cervical Cancer, Negative For Intraepithelial Lesion Or Malignancy, Atypical Squamous Cells of Undetermined Significance
Peking University People's Hospital
Observational
17,875
Beijing, Zhengzhou, Changsha, Chengdu, Hangzhou
2022-11-19
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Hangzhou
2022-11-18
Active, closed
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Active, closed
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Active, closed
Bayer
Phase 1
284
Beijing, Shenzhen, Hangzhou
2022-11-04
Active, closed
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou
2022-11-01
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Beijing, Changchun, Changsha, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2022-10-13
Active, closed
InxMed (Shanghai) Co., Ltd.
Phase 1/2
140
Hangzhou, Bengbu, Changsha, Fuzhou, Ganzhou, Nanjing, Wuhan, Xuzhou
2022-10-12
Active, closed
InventisBio Co., Ltd
Phase 1/2
92
Hangzhou
2022-10-12
Active, closed
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Active, closed
Genmab
Phase 3
72
Baoding, Beijing, Changchun, Chengdu, Dalian, Guandong, Guangxi, Hangzhou
2022-10-08
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2022-10-01
Recruiting
Wuhan YZY Biopharma Co., Ltd.
Phase 1/2
116
Hangzhou
2022-09-30
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
200
Hangzhou
2022-09-27
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Chaoyang, Chengdu, Hangzhou, Jinhua, Nanjing, Wuhan
2022-09-19
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
35
Hangzhou
2022-09-17
Active, closed
AstraZeneca
Phase 3
594
Baoding, Beijing, Changsha, Chengdu, Deyang, Guangzhou, Hangzhou, Hefei
2022-09-15
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
324
Shanghai, Hangzhou
2022-09-15
Recruiting
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
NCT05652192Advanced Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
37
Hangzhou
2022-09-15
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou, Hefei, Jinhua
2022-09-13
Recruiting
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Recruiting
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
Singlera Genomics Inc.
Observational
2,000
Hangzhou
2022-09-05
Recruiting
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
NCT06822413Cancer Diagnosis, Liver Cancer, Adult, Cancer Screening, Colorectal Cancer (CRC)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Nanchang, Shanghai, Hangzhou
2022-09-01
Recruiting
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
504
Hangzhou
2022-08-31
Recruiting
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Recruiting
Shanghai Virogin Biotech Co., Ltd.
Phase 1
30
Hangzhou
2022-08-23
Rows per page Showing 1001–1500 of 1819
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,819 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,098 of the 1,819 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 309 have not yet opened recruitment, 370 are active but closed to new participants, and 42 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.